Science Explorer Back to mapMap
Discussion
Topic · Surgery

Management of metastatic bone disease

Management of metastatic bone disease is a research topic within Surgery. Science Explorer counts 22k research works in it since 1950. 10.0% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the management of spinal metastatic tumors, including the use of radiotherapy and surgical strategies for palliative treatment. It explores prognostic factors, vertebral compression fractures, and the role of stereotactic radiosurgery in addressing metastatic epidural spinal cord compression. The cluster also discusses the challenges and advancements in managing bone metastases in the spine.

  • Spinal Metastases
  • Metastatic Spine Tumors
  • Radiotherapy
  • Surgical Management
  • Palliative Treatment
  • Prognostic Factors
  • Vertebral Compression Fracture
  • Stereotactic Radiosurgery
  • Metastatic Epidural Spinal Cord Compression
  • Bone Metastases
Research works
22k
fractional, since 1950
In the world top 10%
2.2k
per year above
Top-10% rate
10.0%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+6%
the tick is no change
Largest producer
United States
37% of the 10 largest, 2022-now
Management of metastatic bone disease

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Management of metastatic bone disease research?

By volume, the United States and China publish the most (1.3k and 689 works in 2022-now).

By volume, 2022-now

  1. 1 United States 1.3k works
  2. 2 China 689 works
  3. 3 Japan 303 works
  4. 4 Germany 248 works
  5. 5 India 216 works
  6. 6 United Kingdom 186 works
  7. 7 Italy 183 works
  8. 8 Canada 149 works
  9. 9 France 118 works
  10. 10 Türkiye 107 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 36.5%China: 19.9%Japan: 8.7%Germany: 7.2%6 others listed: 27.7%37%largest
United States1,266 · 36.5%China689 · 19.9%Japan303 · 8.7%Germany248 · 7.2%6 others listed959 · 27.7%

Shares of the rows listed above, not of the whole node.

Which institutions lead Management of metastatic bone disease research?

By volume in 2022-now, Harvard University publishes the most Management of metastatic bone disease research, followed by The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center.

By volume, 2022-now

  1. 1 Harvard UniversityUnited States 65 works
  2. 2 The University of Texas MD Anderson Cancer CenterUnited States 45 works
  3. 3 Memorial Sloan Kettering Cancer CenterUnited States 43 works
  4. 4 Peking UniversityChina 39 works
  5. 5 Mayo ClinicUnited States 39 works
  6. 6 University of TorontoCanada 39 works
  7. 7 Johns Hopkins UniversityUnited States 35 works
  8. 8 All India Institute of Medical SciencesIndia 29 works
  9. 9 Sichuan UniversityChina 27 works
  10. 10 Sun Yat-sen UniversityChina 26 works

Who are the leading researchers in Management of metastatic bone disease?

The most-cited researchers publishing on Management of metastatic bone disease include Elaine R. Mardis, Cyrus Cooper and Jun Wang.

  1. 1 Elaine R. Mardis United States 346k citations
  2. 2 Cyrus Cooper United Kingdom 342k citations
  3. 3 Jun Wang China 340k citations
  4. 4 Jeremy Grimshaw Canada 281k citations
  5. 5 Jean‐Louis Vincent Belgium 262k citations
  6. 6 Ralph B. D’Agostino United States 255k citations
  7. 7 Roger Chou United States 248k citations
  8. 8 Graham A. Colditz United States 233k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Management of metastatic bone disease?

The most cited paper in Management of metastatic bone disease is "Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer" (Jennifer S. Temel, Joseph Andrew Greer, Alona Muzikansky et al., 2010), with 7,560 citations. Next come "Tolerance of normal tissue to therapeutic irradiation" (4,510) and "Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer" (2,544).

Most cited papers
#PaperReleasedCitations
1 Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer Jennifer S. Temel, Joseph Andrew Greer, Alona Muzikansky et al. · New England Journal of Medicine 18 Aug 2010 7,560
2 Tolerance of normal tissue to therapeutic irradiation Bahman Emami, Jacqueline Lyman, Adam S. Brown et al. · International Journal of Radiation Oncology*Biology*Physics May 1991 4,510
3 Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer Robert D Timmerman · JAMA Open access 16 Mar 2010 2,544
4 Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity Robert Edward Coleman · Clinical Cancer Research 15 Oct 2006 2,508
5 Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial David William Andrews, Charles Scott, Paul W. Sperduto et al. · The Lancet May 2004 2,435
All 100 most cited papers, with filters and sorting

Where is Management of metastatic bone disease research done?

The largest centres of Management of metastatic bone disease research in 2022-now are Beijing (China), New York (United States), Shanghai (China) and Tokyo (Japan). Among places with at least 20 works in it, it is an unusually large share of all research in Rockville Centre.

Largest cities, 2022-now

  1. 1 BeijingChina 102 works
  2. 2 New YorkUnited States 91 works
  3. 3 ShanghaiChina 66 works
  4. 4 TokyoJapan 64 works
  5. 5 HoustonUnited States 62 works
  6. 6 SeoulSouth Korea 59 works
  7. 7 BostonUnited States 59 works
  8. 8 TorontoCanada 54 works
  9. 9 MoscowRussia 51 works
  10. 10 BaltimoreUnited States 47 works

Where it is the local speciality

  1. Rockville CentreUS · 24.8 works39×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Management of metastatic bone disease than the world average.

See Management of metastatic bone disease on the map

Where is the best place to study Management of metastatic bone disease?

Among universities, judged by research, Utrecht University, Harvard University and Humanitas University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%mean 18.24%fractional works in this field (log) →share of work in the world top 10% →Utrecht UniversityHumanitas UniversityUniversity of TorontoHarvard University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Utrecht UniversityNetherlands 69.423.3%4.3×12 +30.8%
2Harvard UniversityUnited States 67.514.4%5.0×65 -23.9%
3Humanitas UniversityItaly 67.322.4%14.5×8 +32.3%
4University of TorontoCanada 64.615.7%4.7×39 0.0%
5National University of SingaporeSingapore 57.323.2%2.2×10 +94.0%
6Stanford UniversityUnited States 56.218.1%3.1×19 +6.8%
7University of ZurichSwitzerland 54.619.7%4.2×12 +24.8%
8Johns Hopkins UniversityUnited States 53.611.7%5.6×35 -18.0%
9Heidelberg UniversityGermany 52.816.8%6.5×20 +0.3%
10New York UniversityUnited States 51.817.1%3.1×14 +69.6%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Management of metastatic bone disease, country by country

Is Management of metastatic bone disease research growing?

Output in 2022-2025 was 6% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Management of metastatic bone disease.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Management of metastatic bone disease as a percentage of every work published that year, 0.019% in 2024.

still counting0.010%0.020%0.030%Management of metastatic bone disease0.020% in 202519801990200020102020

Fractional works of Management of metastatic bone disease over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Management of metastatic bone disease9.9% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Management of metastatic bone disease. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.